Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Post by LordoftheMarketon Jan 28, 2018 9:42pm
112 Views
Post# 27451608

ISOL now partnered with LiveCare Health Canada

ISOL now partnered with LiveCare Health Canada

Isodiol International Inc. Announces Licensing Agreement With Livecare Health Canada Inc. and Appoints Dr. Amit Mathur to Medical Advisory Board

By GlobeNewswire,  January 26, 2018, 10:45:00 AM EDT

 

VANCOUVER, British Columbia, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the "Company" or "Isodiol"), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has signed a licensing agreement with Livecare Health Canada Inc. (Livecare), an organization founded and operated by Doctors dedicated to giving patients access to quality, real-time healthcare, regardless of where they are located.
 

Livecare is a Vancouver-based company committed to empowering health care through technology.  Founded by Dr. Mark Godley in 2012, they offer digital technologies that connect Doctors & Allied Health Care Providers to their Patients via secure, encrypted, face-to-face video and messaging.

Under the terms of the licensing agreement, Isodiol will license the Telehealth Platform (Platform) and operate it under a white label in connection with the marketing of all its products.  The license shall grant Isodiol the exclusive right to use the Platform relating to all cannabis, cannabis-derived, cannabinoid and phytoceutical products and related services.   Livecare will customize and convey the Platform for Isodiol and will assist in marketing and commercializing the Platform on a global scale.

The Platform is generally described as an interconnectivity network with a cloud-based user interface that provides access by multiple categories of users, including patients, physicians, other medical professionals, pharmaceutical providers, and on personal computing devices to deliver health and wellness solutions without regard to the physical location of the users.

"Isodiol is extremely proud of this innovative step, where our consumers will now have the ability to consult with medical experts via the Telehealth Platform technology," said CEO of Isodiol, Marcos Agramont.  "Our customers are extremely valued and consumers around the globe, particularly in urban areas, will now face little to no inconveniences when seeking health and wellness improvement."

As a part of the licensing agreement, the Company will pay Livecare a royalty dependant on the jurisdiction of commercialization.  The company will also issue 4 quarterly installments of stock in the first year of $250,000 which will be subject to a 36 month escrow schedule.  

In addition to the licensing agreement, Isodiol has appointed Dr. Amit Mathur, co-founder of Livecare, as a medical advisor to the company with focus on implementing a global strategy for the commercialization of the platform.

Over the years, Dr. Mathur has lectured on behalf and participated on national advisory boards to multiple pharmaceutical companies. He has a passion for rural healthcare and has participated in international conferences and seminars in Asia as an advisor and keynote speaker on rural eye health delivery.  He bridges his healthcare and clinic operations experience with his business consulting background to be uniquely effective.

"We are excited to welcome Dr. Mathur to the Isodiol family and we are confident that he will be a valuable addition to the team," said Agramont.  "Dr. Mathur will play a valuable role in ensuring communities and rural municipalities will receive greater access to physicians and allied health providers."

For more information on Isodiol, please visit www.isodiol.com

For more information on Livecare please visit www.livecare.ca/

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

About Livecare Health Canada Inc.

Livecare is a Canadian company founded and operated by Doctors dedicated to giving patients access to quality, real-time healthcare, regardless of where they are located. By offering patients the option to use Telehealth, wait and travel times are decreased or eliminated completely, allowing for invaluable timely diagnosis and triage.

Livecare's mission is to develop and implement self-sustaining patient centered community and international telemedicine programs. Livecare aims to provide health care access to all patients, increase the quality of health delivery by providing timely diagnosis and treatment, and reduce the expense to patients, communities, insurance providers and employers by avoiding needless travel costs and absent work days for primary and specialty medical services.

Join Us On Facebook: https://www.facebook.com/isodiol/

Twitter:@isodiol

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

Ir@isodiol.com

www.isodiol.com

MEDIA CONTACT:

Carrie Booze

North 6th Agency

212-334-9753 ext.142

Isodiol@n6a.com



Bullboard Posts